Trypsin given intramuscularly has been observed to significantly shorten the course of acute superficial or deep thrombophlebitis, enabling early ambulation and return to full activity. While several investigators have reported "dramatic" results with respect to subsidence of signs and symptoms of acute inflammation, the influence of trypsin on the underlying thrombus was more difficult to evaluate.1 Interestingly, the reported incidence of embolization has been extraordinarily low, about 1%. To date, no mortalities have been reported following pulmonary embolus. These findings suggest salutary effects on the thrombus. In order to appraise possible lytic effects on human thrombi a preparation for intramuscular administration of trypsin (Parenzyme) was given for prolonged periods to 18 selected patients with chronic recurrent thrombophlebitis. Each patient had a history of recurrent episodes of thrombophlebitis with small to massive, palpable, grossly visible thrombi for at least two years before trypsin treatment.
MATERIALS AND METHODS
The study includes